Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.

<h4>Purpose</h4>Vascular endothelial growth factor receptor (VEGFR2) directed therapies result in a modest survival benefit for patients with advanced esophageal and gastroesophageal (GE) junction cancer. Platelet-derived growth factor receptor (PDGFR) may contribute to escape from VEGFR...

Full description

Bibliographic Details
Main Authors: Yelena Y Janjigian, Efsevia Vakiani, Geoffrey Y Ku, Jessica M Herrera, Laura H Tang, Nancy Bouvier, Agnès Viale, Nicholas D Socci, Marinela Capanu, Michael Berger, David H Ilson
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0134731

Internet

https://doi.org/10.1371/journal.pone.0134731

Similar Items